Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: A randomized, three-way crossover study
Article first published online: 18 MAR 2014
© 2014 The Authors. The Journal of Clinical Pharmacology Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
The Journal of Clinical Pharmacology
Volume 54, Issue 6, pages 640–648, June 2014
How to Cite
Shiomi, M., Matsuki, S., Ikeda, A., Ishikawa, T., Nishino, N., Kimura, M. and Irie, S. (2014), Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: A randomized, three-way crossover study. Journal of Clinical Pharma, 54: 640–648. doi: 10.1002/jcph.283
- Issue published online: 3 MAY 2014
- Article first published online: 18 MAR 2014
- Accepted manuscript online: 11 MAR 2014 12:34AM EST
- Manuscript Accepted: 17 FEB 2014
- Manuscript Received: 28 NOV 2013
- 2Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings. HIV AIDS. 2012; 4:5–15., , , et al.
- 3Stribild® (elvitegravir 150 mg / cobicistat 150 mg / emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) tablets; Prescribing Information (United States). Gilead Sciences. Available at http://services.gileadhiv.com/stribild/pdf/pi. Last accessed October 23, 2013.
- 4Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendation on integrase inhibitor use in antiretroviral treatment-naive HIV-infected individuals from the HHS panel on antiretroviral guidelines for adults and adolescents. Rockville, MD: DHHS; [updated October 30, 2013]. Available at http://aidsinfo.nih.gov/contentfiles/upload/AdultARV_INSTIRecommendations.pdf. Last accessed October 31, 2013.
- 6http://www.natap.org/2012/pharm/Pharm_30.htm. Last accessed December 11, 2013., , , et al. Population pharmacokinetics of cobicistat-boosted elvitegravir in adult healthy subjects and HIV-infected patients. 13th International Workshop on Clinical Pharmacology of HIV Therapy, Barcelona, Spain, April 16–18, 2012. Conference Reports. Available at:
- 749th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, United States, September 12–15 2009. Abstract A1-1300., , , et al. Effect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir DF and the pharmacoenhancer GS-9350 as a fixed-dose combination tablet.
- 9A pharmacokinetic study of Viread® 300 mg tablet in healthy Japanese adult male volunteers. J New Rem Clin. 2005; 54(8):941–948..
- 10A pharmacokinetic study of Truvada® tablet in Japanese healthy adult male volunteers. J New Rem Clin. 2006; 55(10):1515–1528., , , et al.
- 16http://img.medscape.com/pi/editorial/conferences/2005/4151/druginteract.pdf: Last accessed January 08, 2014., , , et al. Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada, April 28–30 2005. Abstract 16, Poster 2.9. Available at:
- 22Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012; 379(9835):2429–2438., , , et al.